Reutzel-Edens joined Eli Lilly and Company, where she recognized that it would be challenging to identify and design increasingly complicated drug targets, and instead proposed the use of computation approaches. Through collaborations with the Cambridge Crystallographic Database, Reutzel-Edens founded the Lilly solid form design program. Her research has considered crystal polymorphism and the crystal nucleation. She used computational approaches to identify commercially viable small molecule drug products. To this end, Reutzel-Edens proposed the use of crystal structure prediction to identify pharmaceutical molecules to complement experimental investigations. She has described Olanzapine as “an incredible molecule, a gift to crystal chemistry that keeps on giving,”.
In 2018, Reutzel-Edens was appointed Fellow of the Royal Society of Chemistry. She serves on the editorial boards of CrystEngComm and Crystal Growth and Design. In 2021 Reutzel-Edens joined the Cambridge Crystallographic Database as Head of Science.